Xconomy
OCTOBER 12, 2018
Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million.
Both Sides of the Table
APRIL 6, 2020
If your US-based business is adversely affected by Covid-19 such that you would need to lay off employees imminently and having access to capital would enable you to keep more employees on the payroll then you might be eligible. The NVCA (National Venture Capital Association) Guidelines are below. This is another misconception.
Expert insights. Personalized for you.
74 
Let's personalize your content